BPTH Bio-Path Holdings Inc.: Enterprise Value-to-Revenue Multiple

Public company logo of Bio-Path Holdings Inc. (BPTH)

Bio-Path Holdings (BPTH) is optimizing the development of oncology drugs by outsourcing testing to third-party laboratories. The company is developing RNA therapy to combat resistant forms of leukemia. The EV/Sales trend confirms the current business valuation, with the latest mark standing at . The absence of operating income makes the issuer's financial stability entirely dependent on the results of clinical trials.

Enterprise Value-to-Revenue Ratio: Bio-Path Holdings Inc. (BPTH) for 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Bio-Path Holdings, Inc. (BPTH)

- market price and analyst price targets:
Fundamental company valuation:Bio-Path Holdings, Inc. BPTH
Mass-produced product of biopathholdings.com

The EV/Sales metric determines the enterprise value of a business, including net debt, relative to sales volume, allowing for an assessment of revenue generation efficiency regardless of the financing structure. When analyzing the EV/Sales trend, an investor must correlate the ratio with the operational resilience of Bio-Path Holdings (BPTH), where the reliability of DNA drug logistics and the preservation of reagents during transport serve as critical value drivers.